VISEN Pharmaceuticals
维升药业
02561.HK
Biopharmaceutical company developing treatments for endocrinology diseases in Greater China, with a weekly long-acting growth hormone therapy for pediatric growth hormone deficiency and pipeline candidates for achondroplasia and chronic hypoparathyroidism, in-licensed from Ascendis Pharma.
Biotech & PharmaChapter 18ASponsorsMorgan Stanley · JefferiesCounselCooley
Filings
The documents are on HKEXnews; we link to the originals.
| 2025-03-13 | Prospectus | HKEXnews |
Matters the filing discloses
From the company’s latest filing; open a kind of matter to see how other companies disclosed it.